When Eric Karlson’s lymphoma went into complete regression in 2009, Steven Rosenberg and James Kochenderfer knew they were making history—for the first time, they had cured a patient by using genetically modified cell therapy, specifically, anti-CD19 CAR-T cells.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe